PRAX
Praxis Precision Medicines, Inc.
A biopharmaceutical company developing treatments for brain disorders like epilepsy and essential tremor, using two platforms—Cerebrum for small-molecule drugs and Solidus for antisense oligonucleotide therapies. Its lead candidates include ulixacaltamide for essential tremor and seizure-fighting drugs like relutrigine. Founded in 2015 as EpiPM Therapeutics, it took its name from the Greek "praxis," meaning "to do"—turning scientific theory into practical treatment.
CUSIP: 74006W207HealthcareUS2 holders
Total Value
$41.21M
Total Shares
127.9K
Net Share Change
+97.9K
Activity
2 buying
Investor
Value
Shares
Weight
Change
